Loading…
Crinetics Pharmaceuticals, Inc. is projected to rise to $95.56 by 2027, a +14% move from its current price of $83.58. CRNX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $80.64 | $83.59 | $86.64 | +0.01% |
| Jul 14 | $79.45 | $83.59 | $87.95 | +0.01% |
| Jul 15 | $78.56 | $83.60 | $88.96 | +0.02% |
| Jul 16 | $77.81 | $83.60 | $89.83 | +0.03% |
| Jul 17 | $77.16 | $83.61 | $90.60 | +0.04% |
| Jul 18 | $76.58 | $83.62 | $91.30 | +0.04% |
| Jul 19 | $76.04 | $83.62 | $91.95 | +0.05% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $76.04 | $83.62 | $91.95 | +0.05% |
| Week 2 | $73.15 | $83.66 | $95.69 | +0.10% |
| Week 3 | $71.01 | $83.71 | $98.67 | +0.15% |
| Week 4 | $69.26 | $83.75 | $101.27 | +0.20% |
| Week 5 | $67.76 | $83.79 | $103.62 | +0.25% |
| Week 6 | $66.43 | $83.83 | $105.79 | +0.30% |
| Week 7 | $65.24 | $83.87 | $107.84 | +0.35% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors.
The company is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Crinetics Pharmaceuticals, Inc. (CRNX) is a healthcare company with a current price of $83.53, a market capitalization of $8.84B, and a rank of 1003.
The stock is traded in the healthcare sector and carries a market value of $8.84B with a rank of 1003 by market capitalization.
The overall price outlook is favorable on the longer horizon, with the forecasted average price rising across multiple years: 2026 avg $83.53, 2027 avg $93.28, 2030 avg $158.62, and 2050 avg $645.30, with a max forecast up to $251.46 by 2030 and as high as $1,389.92 by 2050.
From 2028 onward the forecast is labeled BULLISH, signaling meaningful upside potential over the multi-year horizon.
A major floor 81.3% below — a decisive break under it would weaken the trend.
The nearest floor, 61.0% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 40.7% above — clearing it would confirm fresh momentum.
Key CRNX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CRNX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $75.25 | Buy | $74.96 | Buy |
| MA 10 | $56.82 | Buy | $63.33 | Buy |
| MA 20 | $46.02 | Buy | $52.47 | Buy |
| MA 50 | $40.46 | Buy | $43.97 | Buy |
| MA 100 | $39.66 | Buy | $41.90 | Buy |
| MA 200 | $42.87 | Buy | $41.17 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 93.15 | Sell |
| Stoch RSI (14) | 99.69 | Sell |
| CCI (20) | 166.78 | Buy |
| Williams %R (14) | -0.08 | Info |
| MACD (12,26,9) | 5.72 | Buy |
| ROC (12) | 132.75 | Buy |
| Bollinger %B (20,2) | 1.00 | Neutral |
| Stochastic %K (14) | 99.92 | Sell |
| TRIX (15) | 1.86 | Buy |
| Awesome (5,34) | 33.78 | Buy |
| Ultimate (7,14,28) | 96.76 | Sell |
| Momentum (10) | 48.59 | Buy |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 95.15 | Sell |
| ADX (14) | 34.17 | Buy |
| ATR (14) | 3.09 | Info |
The 30-day technical picture is BULLISH with RSI14 at 90.
Near-term indicators show the stock trading within a 30-day range of $64.42 to $108.31, with a SMA50 of $37.74 and a SMA200 of $42.13. Support is at $32.61 and resistance at $83.53.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $32.61 | $83.58 | $114.78 | 0% | Neutral | |
| $73.86 | $95.56 | $132.07 | +14% | Neutral | |
| $88.28 | $118.64 | $171.76 | +42% | Bullish | |
| $104.78 | $145.36 | $218.18 | +74% | Bullish | |
| $114.35 | $163.19 | $252.45 | +95% | Bullish | |
| $119.29 | $174.71 | $277.44 | +109% | Bullish | |
| $109.08 | $163.70 | $266.11 | +96% | Bullish | |
| $118.43 | $181.87 | $301.93 | +118% | Bullish | |
| $143.17 | $224.75 | $380.41 | +169% | Bullish | |
| $158.74 | $254.53 | $438.59 | +205% | Bullish | |
| $185.95 | $328.84 | $610.36 | +293% | Bullish | |
| $335.80 | $708.40 | $1,462.92 | +748% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $32.61 | $83.58 | $99.42 | +0.00% |
| August 2026 | $67.83 | $80.74 | $99.16 | -3.40% |
| September 2026 | $70.03 | $84.13 | $104.83 | +4.20% |
| October 2026 | $73.30 | $88.77 | $111.96 | +5.52% |
| November 2026 | $72.70 | $88.64 | $112.93 | -0.15% |
| December 2026 | $72.75 | $89.26 | $114.78 | +0.70% |
Click any year to see its month-by-month CRNX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, CRNX is projected to trade between $32.61 and $114.78, averaging $83.58 — a potential gain of 0% from today's $83.58. Price action looks broadly range-bound.
Crinetics Pharmaceuticals, Inc.'s 2027 outlook centres on $95.56, within a $73.86 to $132.07 range. That is up +14% on the projected 2026 average. That marks a +14% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, CRNX could reach as high as $171.76, with a base case around $118.64 and support toward $88.28 — roughly +42% from $83.58. Momentum favours further upside here.
Expect CRNX to range from $104.78 to $218.18 through 2029. The $145.36 average target implies a +74% move from current prices. That is up +23% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The CRNX price prediction for 2030 points to an average of $163.19 (low $114.35, high $252.45) — a potential gain of +95% on today's $83.58. Momentum favours further upside here.
In 2031, CRNX is projected to trade between $119.29 and $277.44, averaging $174.71 — a potential gain of +109% from today's $83.58. That is up +7% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Crinetics Pharmaceuticals, Inc.'s 2032 outlook centres on $163.70, within a $109.08 to $266.11 range. That is -6% versus the projected 2031 average. That marks a +96% change versus current levels. Momentum favours further upside here.
By 2033, CRNX could reach as high as $301.93, with a base case around $181.87 and support toward $118.43 — roughly +118% from $83.58. Buyers look set to stay in control over this stretch.
Expect CRNX to range from $143.17 to $380.41 through 2034. The $224.75 average target implies a +169% move from current prices. That is up +24% on the projected 2033 average. Momentum favours further upside here.
The CRNX price prediction for 2035 points to an average of $254.53 (low $158.74, high $438.59) — a potential gain of +205% on today's $83.58. Buyers look set to stay in control over this stretch.
In 2040, CRNX is projected to trade between $185.95 and $610.36, averaging $328.84 — a potential gain of +293% from today's $83.58. That is up +29% on the projected 2035 average. Momentum favours further upside here.
Crinetics Pharmaceuticals, Inc.'s 2050 outlook centres on $708.40, within a $335.80 to $1,462.92 range. That is up +115% on the projected 2040 average. That marks a +748% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in CRNX today (≈ 11.964585 CRNX) could be worth
$8,475.73
+$7,475.73 (+748%) by 2050 · US Dollar
Based on the average projected CRNX price of $708.4 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CRNXwould be worth at today's price.
$1,000 invested in CRNX on Jul 10, 2025 (≈ 31.259769 CRNX) would be worth
$2,612.69
+$1,612.69 (+161.3%) today · 2.61× · US Dollar
Based on a CRNX entry price of $31.99 vs. today's $83.58.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $42.23 | $1,979.16 | +97.9% |
| 1 month ago | $34.32 | $2,435.31 | +143.5% |
| 3 months ago | $39.44 | $2,119.17 | +111.9% |
| 6 months ago | $55.35 | $1,510.03 | +51.0% |
| 1 year ago | $31.99 | $2,612.69 | +161.3% |
| All time (5.0y) ago | $20.01 | $4,176.91 | +317.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CRNX forecast.
Our base-case forecast reaches $170.00 around 2031.
Implied market cap at $170.00: $17.99B
The multi-year forecast points to sustained upside, with the 2026 average price at $83.53 and the 2050 average price at $645.30, indicating a substantial long-run climb from the near term.
Year-by-year highlights include 2027 avg $93.28, 2028 avg $114.18, 2029 avg $142.39, 2030 avg $158.62, 2031 avg $166.54, 2032 avg $154.37, 2033 avg $169.97, 2034 avg $209.07, 2035 avg $238.70, 2040 avg $295.89, and 2050 avg $645.30. The corresponding max prices reach $251.46 in 2030 and rise to $1,389.92 in 2050, with ROIs rising from 0 in 2026 to 672.5 in 2050.
The forecast sentiment shifts from NEUTRAL in 2026 and 2027 to BULLISH from 2028 onward, reflecting the expected upside path. These figures are estimates and not guarantees.
Tap a question to reveal the answer.
2030 avg $158.62, min $108.48, max $251.46; ROI 89.9; sentiment BULLISH.
Forecasts show bullish sentiment from 2028 onward, with 2028 avg $114.18, 2029 avg $142.39, 2030 avg $158.62, and 2050 avg $645.30; ROI rises to 672.5 by 2050.
Yes, the 2030 max is $251.46, crossing $250; longer-range max reaches $1,389.92 by 2050.
Current price is $83.53; market cap is $8.84B.
The 30-day range is $64.42 to $108.31.
Crinetics Pharmaceuticals, Inc. Community Discussion
0Share your Crinetics Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.